Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation
Non-small Cell Lung CancerThis is a phase I/IIa, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of H002 when given orally in patients with active EGFR mutation locally advanced or metastatic non-small cell lung cancer (NSCLC). The study will contain two parts: Part A is dose escalation phase (i.e., Phase I) and Part B is dose expansion phase (i.e., Phase IIa).
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
Lung CancerNon Small Cell Lung Cancer5 moreA Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.
This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With...
Relapsed and/or Refractory Multiple MyelomaThis is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0591CP in patients with relapsed and/or refractory multiple myeloma.
Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma
MelanomaThe study was a single-arm study designed to evaluate the efficacy and safety of Chidamide combined with Toripalimab.
Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With...
Diffuse Midline GliomaH3 K27M-MutantThis phase I, first-in-human trial tests the safety, side effects, and best dose of genetically modified cells called KIND T cells after lymphodepletion (a short dose of chemotherapy) in treating patients who are HLA-A*0201-positive and have H3.3K27M-mutated diffuse midline glioma. KIND T cells are a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory into KIND T cells so they will recognize certain markers found in tumor cells. Drugs such as cyclophosphamide and fludarabine are chemotherapy drugs used to decrease the number of T cells in the body to make room for KIND T cells. Giving KIND T cells after cyclophosphamide and fludarabine may be more useful against cancer compared to the usual treatment for patients with H3.3K27M-mutated diffuse midline glioma (DMG).
Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer
Effect of DrugThis study is to examine the anticancer activity of the combination therapy with all-trans retinoic acid and nivolumab in patients with chemotherapy-refractory advanced or metastatic pancreatic adenocarcinoma.
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced,...
Biliary Tract CancerCholangiocarcinoma2 moreThis is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.
A Study of ABI-2280 Vaginal Tablet in Participants With Cervical Intraepithelial Neoplasia
Cervical Intraepithelial NeoplasiaThis is an open-label study to evaluate the safety, tolerability, and efficacy of ABI-2280 in participants with cervical squamous intraepithelial lesions. This study is divided into 2 parts - Part A and Part B. Part A consists of 3 dose escalating cohorts. Part B is a dose expansion cohort. Participants will self-administer ABI-2280.
Erector Spinae Block for Thoracic Surgery
Pulmonary NeoplasmPulmonary Cancer3 moreThe aim of this study is to determine if erector spinae injections with bolus infusions with local anesthetic decrease postsurgical pain and opioid consumption in patients undergoing pulmonary resection surgery.
HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC
Liver CancerPatients with unresectable hepatocellular carcinoma will receive hepatic arterial infusion chemotherapy (HAIC) sequential transarterial embolization combined with lenvatinib and tislelizumab.